Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Study of Ibrutinib Maintenance After Reduced-Intensity Conditioning and Allogeneic Hematopoietic Cell Transplantation for Acute Leukemia

NCT03267186 is registered in ClinicalTrials.gov with Andrew Rezvani as lead sponsor.

NCT NCT03267186
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03267186 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Study of Ibrutinib Maintenance After Reduced-Intensity Conditioning and Allogeneic Hematopoietic Cell Transplantation for Acute Leukemia
Lead sponsor
Andrew Rezvani
Phase
Phase 2
Overall status
Completed
Start date
September 12, 2017
Completion date
April 30, 2021
Enrollment
8 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

acute biphenotypic leukemia, acute lymphoblastic leukemia, acute myeloid leukemia, chronic myelogenous leukemia, bcr-abl1 positive, hematopoietic cell transplantation recipient